. Author manuscript; available in PMC: 2020 Jul 1.

Published in final edited form as: Dig Dis Sci. 2019 Apr 3;64(7):2031–2038. doi: 10.1007/s10620-019-05595-6

Table 1.

Baseline characteristics

	Overall (n = 149)	1 or 2 HBV revaccination doses administered (n = 87)	3 HBV revaccination doses administered (n = 62)
Mean age, at titer measurement	46.2 (15.1)	44.9 (14.9)	48.1 (15.2)
Age ≥ 40 years (%)	63.1	60.9	66.1
Women (%)	54.4	54.0	54.8
Race/ethnicity
White (%)	77.9	75.9	80.6
Mean BMI (kg/m²)	28.0 (5.9)	27.5 (6.3)	28.7 (5.1)
Type of colitis
Crohn’s disease (%)	72.6	71.3	76.3
Mean/median interval time (days)⁺	678.0/277	260.6/203.5	1061.2/471
IBD medication exposures^±
Any therapy (%)^§	78.5	83.9	71.0
Immunomodulator (%)^¶	57.0	60.9	51.6
Anti-TNF	46.3	51.7	38.7
Dual therapy⁺⁺	26.2	28.7	22.6
Corticosteroids^±±	17.4	19.5	14.5

⁺

Interval time between last vaccination received and titer measurement

^±

Drug exposures within 6 months of titer level measurements

^§

Including immunomodulator, anti-TNF, and corticosteroid therapy

^¶

Including azathioprine, 6-mercaptopurine, and methotrexate therapy

⁺⁺

Immunomodulator therapy and anti-TNF therapy

^±±

Including prednisone (po), budesonide (po/pr), and hydrocortisone therapy (po/pr)

HBV hepatitis B virus, BMI body mass index, IBD inflammatory bowel disease, anti-TNF anti-tumor necrosis factor